Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsActivity-based drug searching looks for molecules that produce similar biological effects, even when their chemical structures are quite different. That makes it a complement to the familiar structure-similarity search. The Chemical Checker, described in a 2020 report, assembled bioactivity records for approximately 800,000 molecules and represented each one across five biological levels. Researchers used those profiles to propose candidates for follow-up experiments, including compounds predicted to counter Alzheimer’s-associated mutation effects and compounds that might mimic three biologic drugs.
The demonstrations were computational predictions followed by cellular experiments. They do not establish a medicine, a treatment, or a benefit in patients.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Drugs: From Discovery to Approval | $59.12 | Buy on Amazon |
| 2 |
|
Basic Principles of Drug Discovery and Development | $268.00 | Buy on Amazon |
| 3 |
|
Textbook of Drug Design and Discovery | $55.19 | Buy on Amazon |
| 4 |
|
Computational Drug Discovery and Design (Methods in Molecular Biology, 2714) | $139.46 | Buy on Amazon |
| 5 |
|
Drugs: From Discovery to Approval | $135.33 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
Why structure-only searching can miss useful candidates
A conventional discovery workflow often starts with a molecule known to have a desirable property. Scientists then search for other compounds with similar chemical structures, on the assumption that related structures may behave in related ways. This is valuable because structure can reveal shared chemical features, likely binding motifs, and synthetic relationships.
Biology is less tidy than that assumption. Two molecules can look unrelated on paper yet perturb the same targets, pathways, or cellular processes. A structure search may therefore overlook a potentially useful chemical class simply because it is too distant from the original molecule in chemical space.
#1 Best Overall
An activity-based search changes the question. Instead of asking only, “Which molecules resemble this structure?”, it asks, “Which molecules produce a similar pattern of biological effects?” The answer can include structurally novel compounds that would not appear near the starting molecule in a conventional similarity search.
The approach is not a replacement for structural analysis. It adds another route to candidate generation, after which researchers still need to examine mechanism, selectivity, formulation, toxicity, and other properties.
What the Chemical Checker is designed to compare
The Chemical Checker was presented as a way to organize heterogeneous bioactivity information into comparable molecular fingerprints. Its report-era collection contained around 800,000 molecules, a count reported for 2020 rather than a verified current total. The records were curated from existing databases.
Recommended Free Tools
Each molecule was described at five levels. Every level was divided into five subcategories, allowing a compound to be compared from basic chemistry through biological effects and clinically recorded information.
| Level | What it represents | Examples of questions it can support |
|---|---|---|
| 1. Chemical structure | The molecule’s basic structural representation | Which compounds have related chemical features? |
| 2. Molecular targets | Known binding partners or other biomolecules associated with the compound | Which targets does the compound engage? |
| 3. Biological networks | Network effects that follow when targets are perturbed | Which connected pathways or network regions are affected? |
| 4. Cellular measurements | Cell-level assay results, including measurements such as cytotoxicity | How do cells respond under recorded assay conditions? |
| 5. Clinical information | Recorded indications and side effects | What clinical associations have been reported for the molecule or related activity? |
The fifth level should not be mistaken for clinical proof. It is a layer of recorded information, while the first four mostly describe molecular, network, and cellular observations. A clinical indication in a database does not show that a new activity match is safe or effective for the same use.
Miquel Duran-Frigola, identified as a project leader in the report, described the aim as: “Our goal was to systematically measure the correlation or the connection between each of these bioactivity spaces.” In practice, the resource is intended to show how activity observed in one type of assay relates to activity recorded at other levels.
Structure similarity and activity-profile similarity compared
The two searches answer different questions and depend on different evidence. Running both can expose candidates that either method alone would miss.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →| Comparison point | Structure-based search | Activity-profile search |
|---|---|---|
| What is compared | Chemical representations and structural features | Recorded biological activity across multiple data layers |
| What similarity can reveal | Closely related molecules that may share chemical behavior | Different-looking molecules that may trigger similar biological responses |
| Main data requirement | A usable and sufficiently complete chemical representation | Curated, comparable assay and biological records |
| Typical role | Find analogues, explain structure–activity relationships, and support chemical optimization | Prioritize phenotypic or mechanistic matches beyond the starting molecule’s structural neighborhood |
| Evidence stage in the described platform | Database-level comparison | Database prediction followed by cellular follow-up in the reported examples |
Neither method has a universal performance advantage established by the report. Their usefulness depends on the question, the quality of the starting data, and the type of biological effect being sought.
Rank #3
How an activity-based search fits into discovery work
The following workflow shows how a team could use activity profiles without treating a database match as a finished lead.
- Define the desired property. Specify the phenotype or biological response that matters, such as reversing a mutation-associated cellular effect, changing a pathway readout, or reproducing a known drug-like response. A vague goal produces an ambiguous profile.
- Assemble seed compounds or observations. Start with molecules, perturbations, or assay results linked to the desired property. Include the assay context, cell type, dose or concentration information when available, and the measured endpoint.
- Represent each seed across available layers. Record structural features, known targets, network consequences, cellular measurements, and relevant clinical annotations. Missing layers should remain missing rather than being treated as negative evidence.
- Search for correlated activity profiles. Compare the seed profile with profiles for other molecules. This is where a structurally distant compound can become a candidate: its activity pattern may align even if its scaffold does not.
- Inspect the biological explanation. Check which layers drive the match. A similarity based on the same cellular phenotype but different targets raises a different mechanistic question from a match supported by shared targets and network effects.
- Check chemical and experimental feasibility. Review availability, purity, solubility, assay interference, and whether the candidate can be tested in an appropriate model. Activity similarity cannot resolve these practical issues by itself.
- Run focused validation experiments. Test the highest-priority candidates in cells using controls that distinguish the intended response from nonspecific toxicity or assay artifacts. The reported Chemical Checker work used cellular models for this follow-up.
- Advance only with broader evidence. Reproducibility, mechanism, selectivity, pharmacokinetics, toxicology, and later-stage studies are separate decisions. A profile match is a prioritization signal, not a declaration that a compound is ready for people.
What the 2020 demonstrations found
Counteracting Alzheimer’s-associated mutation effects
The team used the resource to identify compounds predicted to counteract effects of gene mutations associated with Alzheimer’s disease. They then checked the predictions in cellular models. This example tested whether activity information collected largely from other contexts could suggest candidates for a different disease-related question.
The result is best understood as a proof-of-concept for cross-context discovery: a database assembled from existing bioactivity records can generate hypotheses outside the immediate disease area represented by every individual experiment. It is not evidence that any identified compound treats Alzheimer’s disease.
Free tools Windows power users keep installed
One-click scans. No signup required.
Finding compounds that might mimic biologic drugs
The report also describes predictions of compounds that might mimic the biological action of three biologic drugs. Laboratory experiments confirmed the reported predictions, and the article characterized the success rate as high without supplying a numerical percentage.
That wording supports confidence that the team obtained encouraging experimental matches, but it does not support a calculated accuracy figure. The experiments also do not establish that a small molecule has the same safety, dosing behavior, durability, or therapeutic effect as a biologic medicine in humans.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why the source data determine the quality of the match
An activity profile is only as informative as the observations behind it. The report notes that bioactivity measurements can be incomplete and inconsistently reported. Assays may use different cell lines, concentrations, endpoints, exposure times, or data-processing conventions. A shared label such as “active” can therefore conceal important experimental differences.
The collection also drew heavily on cancer cell-line data. That breadth can be useful for learning recurring cellular responses, but it creates a transfer problem when a prediction is made for another disease context. The Alzheimer’s example was explicitly a test of whether those data could generalize; it should not be read as proof that the same performance will hold across diseases.
Researchers should examine the provenance of every influential feature in a match. A candidate supported by several independent assay types is easier to interpret than one driven by a single noisy measurement. Likewise, a profile assembled from well-annotated target and cell data carries a different level of confidence from one filled mostly by sparse clinical annotations.
Best Value
What a positive match does—and does not—establish
- It can establish a prioritization hypothesis: the candidate has a recorded biological pattern related to the pattern of interest.
- It can guide experiments: the match suggests which compounds, pathways, or cellular readouts deserve testing first.
- It does not establish safety or efficacy: no dosage, therapeutic window, or patient benefit follows from database similarity.
- It does not establish a mechanism: correlated profiles can arise through different targets or indirect network effects.
- It does not replace validation: cellular confirmation is preclinical evidence, not a human trial or an approval decision.
Patrick Aloy, another project leader quoted in the report, explained the network layer this way: “Then, when you interfere with the activity of one of these targets, most of the time these perturbations will spread throughout the cellular networks – this is the third level that we called networks.” That observation explains why a compound’s useful signature may extend beyond its immediate binding partner, while also showing why interpretation requires more than a single target label.
Access, age of the platform, and practical checks
The 2020 account described the Chemical Checker as available through an open-access online platform. That description is historical. Current uptime, access terms, database coverage, release version, and feature set have not been established here, so users should verify those details directly before building a workflow around it.
The approximate 800,000-molecule figure likewise belongs to the report-era collection. It should not be presented as the platform’s current size. A live user should record the release date and version used, because profile contents and annotations can change as source databases are updated.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Before relying on a result, document:
- the platform release or access date;
- the assay and cell context behind the matching features;
- which of the five levels contributed to the similarity;
- any missing or contradictory measurements;
- the independent experiment planned to test the prediction.
Where this strategy is most useful
Activity-profile searching is especially attractive when the desired property is phenotypic, when known useful chemistry is structurally narrow, or when a team wants to find new scaffolds with a familiar biological signature. It can also connect information that normally sits in separate databases: chemical structures, target annotations, network perturbations, cellular assays, indications, and side-effect records.
Structure searches remain essential for analogue design, synthetic planning, intellectual-property analysis, and interpreting structure–activity relationships. An effective discovery program can use structure to control chemical diversity and activity profiles to broaden biological hypotheses, then let experiments decide which candidates merit further investment.
The 2020 publication associated with this work is M. Duran-Frigola and colleagues, Nature Biotechnology (2020), DOI 10.1038/s41587-020-0502-7. The accompanying account in Chemistry World, published 27 May 2020, positioned the Chemical Checker as an ambitious resource for connecting these different views of molecular behavior. Roger Linington of Simon Fraser University called the range of perspectives one of its strongest attributes, while stressing its potential value for discovering new lead molecules.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
